“Idiopathic Bence-Jones proteinuria”: a new characterization of an old entity
- 513 Downloads
- 3 Citations
Abstract
Idiopathic Bence-Jones proteinuria (BJP) is a rare plasma cell dyscrasia, of which the clinical and biological characteristics are yet unclear. Historical data suggested that they are at higher risk of progression to multiple myeloma or other related neoplasms, while recent findings are contradictory. To address these open questions, we evaluated a series of both BJP and monoclonal gammopathy of undetermined significance (MGUS) with production of an intact immunoglobulin plus Bence-Jones proteinuria (MGUS+BJP) with long-term follow-up, regarding their clinical characteristics and progression to multiple myeloma, amyloidosis or other related B cell lymphoproliferative disorders. Two hundred and twenty-nine persons fulfilling the 2004 criteria of MGUS were included in the final analyses: 31 had BJP and 198 had MGUS+BJP. At the time of diagnosis, significantly more persons in the BJP group had renal impairment, anaemia and polyneuropathy. A more detailed analysis revealed discrepancies between the serum and urine light chain type in nine cases, reflecting clonal heterogeneity. The number of disease progressions was higher in MGUS+BJP (n = 30) when compared to BJP (n = 1), with a rate of 1.6 and 0.4 progressions per 100 person-years, respectively. In conclusion, BJP has distinct clinical characteristics and a lower risk of progression when compared to MGUS+BJP. Our data suggest that MGUS+BJP being closer to malignant transformation may be due to the higher portion of genetically heterogeneous, pre-malignant plasma cell subclones.
Keywords
MGUS Bence-Jones Clonality Light chains Progression MyelomaNotes
Acknowledgments
The authors thank Werner Klotz for the access to the primary data. This work was supported by a grant of the “Österreichische Krebshilfe-Krebsgesellschaft Tirol”.
Conflict of interest
The authors declare that they have no conflict of interest.
References
- 1.Korde N, Kristinsson SY, Landgren O (2011) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117(21):5573–5581. doi: 10.1182/blood-2011-01-270140 PubMedCrossRefGoogle Scholar
- 2.Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV (2010) Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 375(9727):1721–1728. doi: 10.1016/s0140-6736(10)60482-5 PubMedCrossRefGoogle Scholar
- 3.Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47(4):673–680PubMedGoogle Scholar
- 4.Hopkins FG (1911) A study of Bence-Jones protein, and of the metabolism in three cases of Bence-Jones proteinuria. J Physiol 42(3):189–250PubMedGoogle Scholar
- 5.Kyle RA, Greipp PR (1982) "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 306(10):564–567. doi: 10.1056/NEJM198203113061002 PubMedCrossRefGoogle Scholar
- 6.Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106(3):812–817. doi: 10.1182/blood-2005-03-1038 PubMedCrossRefGoogle Scholar
- 7.Fiegl M, Greil R (2002) Monoclonal gammopathy of undetermined significance. N Engl J Med 346(26):2087–2088. doi: 10.1056/NEJM200206273462614, author reply 2087–2088PubMedCrossRefGoogle Scholar
- 8.Eisele L, Durig J, Huttmann A, Duhrsen U, Assert R, Bokhof B, Erbel R, Mann K, Jockel KH, Moebus S, Heinz Nixdorf Recall Study Investigative G (2012) Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany. Ann Hematol 91(2):243–248. doi: 10.1007/s00277-011-1293-1 CrossRefGoogle Scholar
- 9.Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003). Br J Haematol 121(5):749–757Google Scholar
- 10.Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346(8):564–569. doi: 10.1056/NEJMoa01133202 PubMedCrossRefGoogle Scholar
- 11.Jaffe E, Harris N, Stein H, Vardiman J (2001) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. World Health Organization (WHO) classification of tumors. World Health Organization, LyonGoogle Scholar
- 12.Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F (2003) Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis Off J Natl Kidney Found 42(6):1154–1163CrossRefGoogle Scholar
- 13.Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA, International K, Monoclonal Gammopathy Research G (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120(22):4292–4295. doi: 10.1182/blood-2012-07-445304 CrossRefGoogle Scholar
- 14.Dalakas MC, Engel WK (1981) Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Ann Neurol 10(1):45–52. doi: 10.1002/ana.410100109 PubMedCrossRefGoogle Scholar
- 15.Rajabally YA (2011) Neuropathy and paraproteins: review of a complex association. Eur J Neurol Off J Eur Fed Neurol Soc 18(11):1291–1298. doi: 10.1111/j.1468-1331.2011.03380.x Google Scholar